Literature DB >> 31107305

"FANMI": A Promising Differentiated Model of HIV Care for Adolescents in Haiti.

Lindsey K Reif1, Vanessa R Rivera1, Rachel Bertrand2, Marie E Belizaire2, Joseph-Marie B Joseph2, Bianca Louis2, Bernadette Joseph2, Benedict Anglade2, Grace Seo1, Patrice Severe2, Vanessa Rouzier2, Jean W Pape1,2, Daniel W Fitzgerald1, Margaret L McNairy1,3.   

Abstract

Entities:  

Year:  2019        PMID: 31107305      PMCID: PMC6692183          DOI: 10.1097/QAI.0000000000002088

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


× No keyword cloud information.

INTRODUCTION

HIV-infected adolescents have poorer outcomes than all other age groups.[1,2] In Haiti, 24,000 adolescents and youth are HIV-infected, with HIV prevalence as high as 2.6%.[3] Retaining adolescents in HIV care is difficult, and studies in Haiti have demonstrated that only 60% remain in care 1 year after initiating antiretroviral therapy (ART).[4] Multiple factors increase adolescents' risk of poor outcomes including physiological and psychological development,[5-7] high risk-taking behavior, and poor decision-making.[8] In 2012, the World Health Organization (WHO) recommended “youth-friendly services” for HIV-infected adolescents, which have improved linkage to care and ART initiation but have not systematically improved retention to the levels needed to achieve the UNAIDS 90-90-90 targets.[6,7] In 2017, the WHO recommended differentiated models of HIV care for adolescents,[9,10] defined as patient-centered services tailored to patients' specific needs and designed to reduce health system inefficiencies.[9] Despite widespread guidance, description and evaluation of adolescent-specific differentiated models of HIV care are limited.[11,12] We report outcomes of a pilot program of a differentiated model of adolescent HIV care called FANMI (“My Family” in Creole) in Haiti.

METHODS

This study took place at GHESKIO (Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections), located in Port-au-Prince, Haiti, which operates the nation's largest adolescent-specific HIV clinic. We conducted a retrospective chart review using routinely collected data from adolescents who participated in the FANMI program from November 2014 to October 2015. Ethics boards at Weill Cornell Medicine and GHESKIO approved this analysis. We developed the FANMI model of care in response to an analysis of standard HIV care at the GHESKIO adolescent clinic which showed just 66% of patients were in care 12 months after initiating ART.[4] We began with focus group discussions with patients and an adolescent community advisory board to identify factors contributing to poor retention in care. Patients reported experiencing extreme rejection by their family and inability to disclose status because of intense stigma, resulting in profound social isolation. Furthermore, patient–provider relationships were limited as visits consisted of short encounters with multiple clinicians. Patients reported peer support groups as the most enjoyable part of care. Our goal was to achieve ≥75% 12-month retention for FANMI to be appropriate for large-scale implementation. FANMI was designed to address barriers including social isolation, family rejection, stigma, and disjointed care with multiple providers (Fig. 1). It is based on a previous model of group care implemented among pregnant women at GHESKIO[13] and was adapted for an adolescent population through quality improvement methods.[14] In FANMI, the same cohort of 5–8 adolescents met monthly to facilitate building close relationships with peers, bolster social support, and reduce stigma by making HIV health management a group norm. Cohorts were stratified by age (10–15 years and 16–20 years) to address adolescents' unique developmental needs. Cohort meetings occurred in a community room, separate from the clinic, to decrease the stigma of attending an HIV clinic. Finally, the structure of each group meeting integrated peer counseling, social activities, and medical care by the same providers each time (a nurse and social worker). This both streamlined care and demedicalized the HIV visit by expanding the visit's focus beyond just clinical care. Group counseling topics included stigma, disclosure, family rejection, and developing coping skills as well as ongoing educational counseling on HIV, risk reduction, and adherence. A nurse provided individual clinical check-ups, point-of-care CD4 testing every 6 months after ART initiation, and ART refills. Adolescents could access the HIV clinic whenever desired or referred.
FIGURE 1.

Description of FANMI intervention. HIV services provided were identical in both cohorts and followed the current WHO guidelines for adolescent HIV treatment.

Description of FANMI intervention. HIV services provided were identical in both cohorts and followed the current WHO guidelines for adolescent HIV treatment. Adolescents aged 10–20 years who tested HIV-positive at the GHESKIO adolescent HIV clinic or in a community-based HIV testing campaign[3] between November 2014 and October 2015 participated in FANMI. All participants received HIV services according to national and WHO guidelines.[15,16] Verbal parental consent and adolescent assent were provided for all HIV testing and treatment. Upon testing HIV-positive, all adolescents received counseling and initiated ART by a physician, with a first-line regimen of tenofovir, lamivudine, and efavirenz. Age, sex, and CD4 count were measured at time of HIV testing. Enrollment in HIV care was defined as the date of an HIV-positive test. ART initiation was defined as documentation of ART start in the clinic electronic medical record (EMR). Retention at 12 months was defined as having a clinic visit between 11 and 13 months from HIV testing. Participants completed a standard survey at enrollment and a follow-up survey at 12 months to assess mental health, social support, and sexual risk behaviors. Viral load was recommended at 12 months after ART initiation. Kaplan–Meier methods estimated the incidence of retention at 12 months with patients censored at time of transfer or attrition from care. Statistical comparisons between survey responses at enrollment and 12 months were made using a 2 proportion z-test.

RESULTS

Fifty adolescents participated in the FANMI program. Median age was 17.5 years [interquartile range (IQR) 15–19], and 76% (n = 38) were female. Median CD4 cell count was 537 cells/mm3 (IQR 339–805) at HIV testing. All adolescents were assessed for ART eligibility and initiated ART the same day as HIV testing (100%; 50/50). At 12 months after ART initiation, 86% (43/50; 95% confidence interval: 74 to 92) of adolescents were retained in care. No deaths were reported, and there was no significant association between age or sex and being retained in care. Surveys administered at enrollment (n = 50) and 12 months (n = 45) assessed depression, social support, and sexual risk behaviors. The proportion of adolescents who reported feeling hopeless in the past 30 days decreased from 38% at enrollment to 20% at 12 months (P = 0.05), and the proportion who reported depression decreased from 34% at enrollment to 17% at 12 months (P = 0.07). The proportion of adolescents reporting a desire for more emotional support from family and friends decreased from 94% at enrollment to 50% at 12 months (P < 0.01), with 52% reporting they had 1 or less close friends with whom they felt at ease to talk about private matters or call on for help at enrollment and only 40% reporting this at 12 months (P = 0.11). The proportion of participants reporting they used a condom every time they had sex increased from 8% at enrollment to 26% at 12 months (P = 0.02). Among 40 adolescents with available viral load test results 12 months from enrollment, 33% had a viral load <1000 copies/μL. This proportion increased to 55% with further follow-up (IQR 1.6–2.6 years). Additional outcomes that underscore the vulnerability of these patients include 10% of adolescents who reported they had exchanged sex for food, rent, or other necessities; 12% reported having been raped; and 90% reported consistent food insecurity. No adolescent was referred to the adolescent HIV clinic for medical issues, and none reported any social harms including increased stigma or unintended disclosure.

DISCUSSION

This study describes a promising model of adolescent-specific HIV care that achieved high retention in care, reduced risk behaviors, and improved mental health. The success of FANMI likely reflects the bundling of multiple structural and behavioral interventions into a combined strategy which collectively intensified social support, reduced stigma, demedicalized HIV care, and integrated clinical care and counseling in a single visit with the same provider to facilitate long-term patient–provider relationships and streamlined services. FANMI builds on several other adolescent models of HIV care. For example, “Saturday Teen Clubs” in Malawi expanded clinic hours to Saturdays, when adolescents received individualized care and participated in crafts and games with peers.[17] Those who attended a club were less likely to be lost from care (odds ratio 0.27; 95% confidence interval: 0.16 to 0.45). Second, in the Zvandiri program in Zimbabwe, HIV-infected adolescents were trained as community adolescent treatment supporters and managed a caseload of patients in their district, providing support through home visits and mobile phone communication.[12,18] Data from 161 participating sites report 12-month retention was 98% among adolescents on ART. FANMI is unique in that it includes adolescents newly diagnosed, not yet defined as stable, and combines multiple strategies into a combination approach. Although FANMI improved behavioral outcomes, rates of depression and desire for more social support at 12 months remain markedly high, reflecting the persistent hardships and complexities of adolescence. The hardships may influence medication adherence as our rates of viral suppression remain far from optimal. Additional behavioral and biomedical interventions coupled with the FANMI model of care are needed to improve adherence. Examples include strengthened adherence counseling, mhealth reminders or virtual group platforms,[19] family interventions, and more potent and/or better tolerated ART regimens such as integrase inhibitors or long-action regimens.[20] In summary, FANMI is a promising, novel model of care for HIV-infected adolescents to improve retention in care as well as risk behaviors and mental health for this extremely vulnerable population. Although this analysis reports data from a small pilot, FANMI is now being evaluated in a large randomized control trial (NCT03286504) in Haiti. If found effective, this model could be scaled up in other resource-limited settings and among other vulnerable populations.
  14 in total

Review 1.  Examining the link between adolescent brain development and risk taking from a social-developmental perspective.

Authors:  Teena Willoughby; Marie Good; Paul J C Adachi; Chloe Hamza; Royette Tavernier
Journal:  Brain Cogn       Date:  2013-10-13       Impact factor: 2.310

2.  Growth in late infancy among HIV-exposed children in urban Haiti is associated with participation in a clinic-based infant feeding support intervention.

Authors:  Rebecca A Heidkamp; Rebecca J Stoltzfus; Daniel W Fitzgerald; Jean W Pape
Journal:  J Nutr       Date:  2012-02-29       Impact factor: 4.798

Review 3.  Youth-friendly services and differentiated models of care are needed to improve outcomes for young people living with HIV.

Authors:  Lindsey K Reif; Margaret L McNairy; Matthew R Lamb; Ruby Fayorsey; Batya Elul
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

4.  Social cognitive development during adolescence.

Authors:  Suparna Choudhury; Sarah-Jayne Blakemore; Tony Charman
Journal:  Soc Cogn Affect Neurosci       Date:  2006-12       Impact factor: 3.436

5.  Community-Based HIV and Health Testing for High-Risk Adolescents and Youth.

Authors:  Lindsey K Reif; Vanessa Rivera; Bianca Louis; Rachel Bertrand; Mireille Peck; Benedict Anglade; Grace Seo; Elaine J Abrams; Jean W Pape; Daniel W Fitzgerald; Margaret L McNairy
Journal:  AIDS Patient Care STDS       Date:  2016-08       Impact factor: 5.078

Review 6.  Zvandiri-Bringing a Differentiated Service Delivery Program to Scale for Children, Adolescents, and Young People in Zimbabwe.

Authors:  Nicola Willis; Tanyaradzwa Napei; Alice Armstrong; Helen Jackson; Tsitsi Apollo; Angela Mushavi; Getrude Ncube; Frances M Cowan
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.731

7.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Authors:  David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen
Journal:  Lancet       Date:  2017-07-24       Impact factor: 79.321

8.  Greater retention in care among adolescents on antiretroviral treatment accessing "Teen Club" an adolescent-centred differentiated care model compared with standard of care: a nested case-control study at a tertiary referral hospital in Malawi.

Authors:  Rachel K MacKenzie; Monique van Lettow; Chrissie Gondwe; James Nyirongo; Victor Singano; Victor Banda; Edith Thaulo; Teferi Beyene; Mansi Agarwal; Allyson McKenney; Susan Hrapcak; Daniela Garone; Sumeet K Sodhi; Adrienne K Chan
Journal:  J Int AIDS Soc       Date:  2017-11       Impact factor: 5.396

Review 9.  The changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents.

Authors:  Annette H Sohn; Rohan Hazra
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

Review 10.  Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review.

Authors:  Olurotimi A Adejumo; Kathleen M Malee; Patrick Ryscavage; Scott J Hunter; Babafemi O Taiwo
Journal:  J Int AIDS Soc       Date:  2015-09-16       Impact factor: 5.396

View more
  4 in total

Review 1.  Models of lifelong care for children and adolescents with chronic conditions in low-income and middle-income countries: a scoping review.

Authors:  Lindsey K Reif; Josefien van Olmen; Margaret L McNairy; Saeed Ahmed; Nande Putta; Raoul Bermejo; Rachel Nugent; Elijah Paintsil; Bernadette Daelmans; Cherian Varghese; Nandita Sugandhi; Elaine J Abrams
Journal:  BMJ Glob Health       Date:  2022-07

2.  Importance of support groups to the health and well-being of vulnerable children and young people living with HIV: a case study of the Kids Clubs program in Haiti.

Authors:  Susan K Settergren; Robert Philippe; Joanne St Louis; Nathaniel Segaren; Sylvie Boisson; Tessa Lewis; Olbeg Désinor; Kesner François
Journal:  BMC Health Serv Res       Date:  2021-03-16       Impact factor: 2.655

3.  Scaling up peer-led community-based differentiated support for adolescents living with HIV: keeping the needs of youth peer supporters in mind to sustain success.

Authors:  Sarah Bernays; Maureen Tshuma; Nicola Willis; Kudzanayi Mvududu; Adrian Chikeya; Juliet Mufuka; Frances Cowan; Webster Mavhu
Journal:  J Int AIDS Soc       Date:  2020-09       Impact factor: 5.396

4.  The FANMI ("my FAMILY" in Creole) study to evaluate community-based cohort care for adolescent and young women living with HIV in Haiti: protocol for a randomized controlled trial.

Authors:  Grace Seo; Joseph Marie Bajo Joseph; Nancy Confident; Esther Jean; Bianca Louis; Tatiana Bell; Rose Cardelle Riche; Marie Elmase Belizaire; Vanessa Rouzier; Alexandra Apollon; Lindsey Reif; Vanessa Rivera; Elaine Abrams; Heejung Bang; Bruce Schackman; Daniel Fitzgerald; Jean W Pape; Margaret L McNairy
Journal:  BMC Public Health       Date:  2019-12-30       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.